Families of children with deadly disease demand access to life-changing treatment

[2nd April, 2025] LONDON, UK – Families of children with the fatal genetic disorder Batten disease are calling on the National Institute for Health and Care Excellence (NICE) to guarantee continued access to a life-changing treatment, at a committee meeting being held tomorrow.

The drug, Brineura® (cerliponase alfa), developed by BioMarin, has been shown to slow the onset of disability and progression of the CLN2 variant of Batten disease in children. Without the therapy, the typical lifespan of a child with the condition is just six to twelve years.

Liz Brownnutt, Chief Executive Officer of the Batten Disease Family Association CIO (BDFA), said: “The Batten disease community would like to know why a decision on Brineura is taking so long. In November 2019, NICE agreed to provide access to the drug for five years under a Managed Access Agreement (MAA), at the end of which a permanent decision about the future of the treatment on the NHS could be made. NICE has held two evaluation meetings, extended the MAA by a further six months and to date, no decision has been taken, instead we have yet another NICE evaluation meeting tomorrow. A diagnosis of Batten disease is a truly devastating one and the delays are creating additional stress and uncertainty for families. We call on NICE to act quickly tomorrow to offer continued hope to those children affected.”

James Weston, parent to Max, who is four years old and has Batten disease, said: “Max’s life has been dramatically impacted by Brineura, a treatment that has allowed him to thrive despite his Batten disease diagnosis. Thanks to early intervention, Max is able to run, talk, and play with his friends – activities that he otherwise would have lost. He is seizure-free and continues to make great strides in his development. Without Brineura, Max would experience a rapid decline in his abilities, leading to the eventual loss of these skills and, tragically, his life. This treatment is not just a medical necessity; it is the key to Max’s future.”

Professor Paul Gissen, who treats children with metabolic diseases at Great Ormond Street Hospital (GOSH) said: “There are an estimated 30-50 children affected by CLN Type 2 Batten disease in the UK – most will not survive past early adolescence. The neurodegenerative condition results in seizures, severe disability, progressive dementia and death. Although Brineura isn’t a cure, it has been shown in clinical trials at GOSH to benefit children, by slowing the rate of decline in their motor and language skills and reducing the loss of brain tissue. It is crucial that these children can continue to access this life-changing treatment.”

In March 2025, families of children with Batten disease protested outside the Houses of Parliament and held meetings with MPs, at the invitation of Sir Ian Botham.

For more information about BDFA, please contact Liz Brownnutt -  lizbrownnutt@bdfa-uk.org.uk.

About BDFA

The Batten Disease Family Association CIO (BDFA) is a national charity which aims to support families, raise awareness and facilitate research into the group of devastating neurodegenerative diseases commonly known as Batten disease.  We are based in Shipley, West Yorkshire but work with children, young people, families and professionals across the UK.

This communication was created with kind support from Richard Oakley at Oxygen Health Communications - richard@oxygenmediacomms.com.